Related Experiment Video
Updated: Feb 11, 2026
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Clinical Pharmacokinetics and Pharmacodynamics of Dalcetrapib
Donald M Black1, Darren Bentley2, Sunny Chapel3
1Dalcor Pharmaceuticals UK Limited, 123 Wellington Road South, Stockport, Cheshire, SK1 3TH, UK. Dblack@dalcorpharma.com.
Abstract:
The cholesterol ester transfer protein (CETP) inhibitor dalcetrapib has been under evaluation for its potential to prevent cardiovascular (CV) events for almost two decades. The current clinical development program, representing new advances in precision medicine and focused on a genetically defined population with acute coronary syndrome (ACS), is supported by a large body of pharmacokinetic and pharmacodynamic data as well as substantial clinical experience in over 13,000 patients and volunteers. Dalcetrapib treatment of 600 mg/day produces significant inhibition of CETP activity, and has been utilized in phase II and III studies, including CV endpoint trials. Numerous studies have investigated the interactions between dalcetrapib and most drugs commonly prescribed to CV patients and have not demonstrated any clinically significant effects. Evaluations in patients with renal and hepatic impairment demonstrate a greater exposure to dalcetrapib than in the non-impaired population, but long-term clinical studies including patients with mild to moderate hepatic and renal dysfunction demonstrate no increase in adverse events. Safety pharmacology and toxicology studies as well as the clinical safety experience support the continuing development of dalcetrapib as an adjunct to 'standard of care' for the ACS population. This article provides a full review of the pharmacokinetics, as well as pharmacodynamics and pharmacology, of dalcetrapib in the context of a large clinical program.
Insights
Dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, shows promise for preventing cardiovascular events in acute coronary syndrome (ACS) patients. Extensive data support its safety and efficacy as an adjunct to standard care.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Precision Medicine
Background:
- Cholesterol ester transfer protein (CETP) inhibition is a therapeutic target for cardiovascular disease.
- Dalcetrapib has undergone extensive evaluation for cardiovascular event prevention over nearly two decades.
- Current development focuses on a genetically defined acute coronary syndrome (ACS) population.
Purpose of the Study:
- To review the pharmacokinetics, pharmacodynamics, and pharmacology of dalcetrapib.
- To evaluate the safety and efficacy of dalcetrapib as an adjunct to standard care in ACS patients.
- To assess drug interactions and effects in patients with renal and hepatic impairment.
Main Methods:
- Phase II and III clinical studies, including cardiovascular endpoint trials.
- Pharmacokinetic and pharmacodynamic assessments.
- Drug interaction studies with commonly prescribed cardiovascular medications.
- Safety pharmacology and toxicology studies.
Main Results:
- Dalcetrapib (600 mg/day) significantly inhibits CETP activity.
- No clinically significant drug interactions were observed with commonly prescribed cardiovascular drugs.
- Patients with mild to moderate renal and hepatic impairment showed no increased adverse events despite greater drug exposure.
- Extensive clinical experience in over 13,000 patients and volunteers supports the safety profile.
Conclusions:
- Dalcetrapib is a well-characterized CETP inhibitor with a favorable safety profile.
- Its development as an adjunct to standard care for ACS patients is supported by substantial data.
- Precision medicine approach in a genetically defined population enhances its therapeutic potential.
More Related Videos
09:18Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study
Published on: March 31, 2022
07:02A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Related Concept Videos
01:21Pharmacodynamics: Overview and Principles
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
01:10Pharmacokinetics: Overview
01:20Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
01:19Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...